Clinical Trials
23 trialsNCT00655655 2024-08-21
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Phase 1 Completed
NCT01525082 2024-02-06
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Stanford University
Phase 2 Completed
NCT00427349 2023-07-05
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03147768 2022-04-06
LTW
Laser Tissue Welding, Inc.
Phase 1 Completed
NCT02259725 2021-12-15
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
University of Southern California
Phase 2 Completed
NCT03189953 2021-06-16
GLP-1-AHH
Radboud University Medical Center
Phase 1/2 Completed
NCT00454363 2020-04-03
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00325104 2017-07-02
Cinacalcet to Treat Familial Primary Hyperparathyroidism
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT01204476 2016-07-15
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00049023 2016-06-21
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
University of Iowa
Phase 1 Completed
NCT00416767 2016-05-30
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT00131911 2014-11-17
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00096083 2013-10-23
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Delcath Systems Inc.
Phase 2 Completed
NCT00602082 2013-08-07
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00027638 2013-06-18
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00075439 2013-06-04
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006368 2013-05-01
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Novartis
Phase 1 Completed
NCT00004074 2013-02-28
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005842 2013-02-11
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00017199 2013-01-31
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005860 2011-04-26
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005910 2008-03-04
Laparoscopy to Remove Pancreatic Tumors (Insulinomas)
National Institutes of Health Clinical Center (CC)
Phase NA Completed